Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06956391 · ClinicalTrials.gov registry record · Phase 2
Ultralow Dose PET Imaging of 18F-FDG Uptake
A Phase 2 study of Cancer and Healthy Volunteer, sponsored by Akiva Mintz.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06956391 is a Phase 2 study of Cancer and Healthy Volunteer that is actively recruiting participants, run by Akiva Mintz. The registered enrollment target is 200 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06956391, a Phase 2 study of Cancer and Healthy Volunteer, is actively recruiting participants, sponsored by Akiva Mintz.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
Conditions Studied
Interventions
- DRUG 18F-FDG
Study Locations (1)
New Jersey
- Nuclear Imaging Institute - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06956391
The ClinicalTrials.gov registry entry for NCT06956391 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Akiva Mintz, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-FDG is the first listed.
NCT06956391 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06956391 about?
NCT06956391 is a clinical study titled "Ultralow Dose PET Imaging of 18F-FDG Uptake". The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fo...
What is the current status of trial NCT06956391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-05-12. Estimated completion is 2030-06-30.
What conditions does trial NCT06956391 study?
This clinical trial studies the following conditions: Cancer, Healthy Volunteer.
What interventions are being tested in trial NCT06956391?
The interventions under investigation include: 18F-FDG (DRUG).
Who is sponsoring clinical trial NCT06956391?
This trial is sponsored by Akiva Mintz, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06956391 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.